Roy Vitkon

6 Weizmann Street
Tel Aviv, TA 64239, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Eligibility Matched Benchmarking of Second-Line Anti-CD19 Chimeric Antigen Receptor-T and Glofit-GemOx (STARGLO) Outcomes in Large B-Cell Lymphoma.

Eligibility Matched Benchmarking of Second-Line Anti-CD19 Chimeric Antigen Receptor-T and Glofit-GemOx (STARGLO) Outcomes in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: April 04, 2026

Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study.

Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study.

Journal: British journal of haematology

Published: March 31, 2026

Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations.

Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations.

Journal: Cancers

Published: March 30, 2026

Spontaneous Metabolic Regression in High-Burden Follicular Lymphoma: A Case Report.

Spontaneous Metabolic Regression in High-Burden Follicular Lymphoma: A Case Report.

Journal: Case reports in hematology

Published: October 21, 2025

ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study.

ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study.

Journal: Haematologica

Published: August 19, 2025

Vagal Nerve Activity Predicts Prognosis in Diffused Large B-Cell Lymphoma and Multiple Myeloma.

Vagal Nerve Activity Predicts Prognosis in Diffused Large B-Cell Lymphoma and Multiple Myeloma.

Journal: Journal of clinical medicine

Published: December 28, 2022

COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge.

COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge.

Journal: Cancer cell

Published: April 27, 2022

Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study.

Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study.

Journal: Therapeutic advances in hematology

Published: May 02, 2021

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.

Journal: Blood advances

Published: April 26, 2021

Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.

Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.

Journal: Annals of hematology

Published: August 05, 2019

Showing 1-10 of 10

Last Updated: 09/26/2026